<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>18069598</identifier>
<setSpec>0034-0634</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Tamargo Menéndez, Juan</dc:author>
<dc:description xml:lang="en">Atrial fibrillation (AFb) is the most common sustained cardiac arrhythmia. Once initiated, AFb alters atrial electrical and structural properties (remodeling) that promotes its maintenance and recurrence. Treatment is directed to restore and maintain the sinus rhythm, to control the ventricular rate and to prevent thromboembolic complications. Recent evidence indicates that angiotensin converting enzyme inhibitors, angiotensin AT1 receptor antagonists and statins modify atrial remodeling and reduce the incidence of AFb, thus possibly representing a new alternative in the treatment of the arrhythmia.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2007 </dc:date>
<dc:title xml:lang="es">Nuevas estrategias en el tratamiento de la fibrilación auricular.</dc:title>
<dc:title xml:lang="en">[New strategies in the treatment of atrial fibrillation].</dc:title>
<dc:publisher>Anales de la Real Academia Nacional de Medicina</dc:publisher>
</metadata>
</record>
</pubmed-document>
